A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

NCT00283634 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

INDUSTRY

Sponsor class

Stopped insufficient efficacy

Conditions

NSCLC

Interventions

DRUG: erlotinib and bortezomib

Sponsor

Millennium Pharmaceuticals, Inc.

Collaborators

[object Object]